Table 1.
Demographic, clinical and laboratory data of HD patients stratified by type of dyslipidaemia
| Parameter | Dyslipidaemia | Without dyslipidaemia | P valuea | Atherogenic dyslipidaemia | Without atherogenic dyslipidaemia | |
|---|---|---|---|---|---|---|
| by K/DOQI criteria | TG/HDL cholesterol ratio | P valuea | ||||
| 5.98 (3.81–30.83) | 2.52 (0.47–3.79) | |||||
| Demographic data | N = 459 | N = 414 | N = 454 | N = 419 | ||
| Male gender, n, % of all | 242 (52.7) | 247 (59.7) | 0.039* | 263 (57.9) | 226 (53.9) | 0.235 |
| Age, years | 66.8 (17.9–95.9) | 67.1 (17.1–92.3) | 0.944 | 66.3 (17.1–92.3) | 68.3 (21.5–95.9) | 0.162 |
| Clinical data | ||||||
| Main cause of ESRD | ||||||
| Diabetic nephropathy, n, % of all | 125 (27.2) | 123 (29.7) | 0.418 | 132 (29.1) | 116 (27.7) | 0.649 |
| Hypertensive nephropathy, n, % of all | 95 (20.7) | 83 (20.0) | 0.878 | 97 (21.4) | 81 (19.3) | 0.509 |
| Chronic glomerulonephritis, n, % of all | 66 (14.4) | 68 (16.4) | 0.457 | 65 (14.3) | 69 (16.5) | 0.431 |
| Chronic tubulointerstitial nephritis, n, % of all | 41 (8.9) | 41 (9.9) | 0.708 | 45 (9.9) | 37 (8.8) | 0.666 |
| Coronary artery disease, n, % of all | 160 (34.9) | 160 (38.6) | 0.246 | 188 (41.4) | 132 (31.5) | 0.002* |
| RRT duration, years | 5.5 (0.2–28.3) | 5.9 (0.1–27.5) | 0.143 | 5.8 (0.1–28.1) | 5.6 (0.2–28.3) | 0.444 |
| HD re-started after graft loss, n, % of all | 25 (5.4) | 22 (5.3) | 0.970 | 25 (5.5) | 22 (5.3) | 0.778 |
| Life with graft, years | 8.7 (0.0–21.0) | 2.1 (0.0–17.0) | 0.014* | 8.3 (0.0–21.0) | 3.0 (0.0–20.0) | 0.082 |
| Dialysis duration, years | 5.4 (0.2–28.3) | 5.9 (0.1–27.3) | 0.009* | 5.7 (0.1–27.3) | 5.6 (0.2–28.3) | 0.613 |
| LF-HD, n, % of all | 224 (48.8) | 194 (46.9) | 0.566 | 199 (43.8) | 219 (52.3) | 0.013* |
| Chronic hepatitis B, n, % of all | 5 (1.1) | 8 (1.9) | 0.555 | 6 (1.3) | 7 (1.7) | 0.884 |
| Chronic hepatitis C, n, % of all | 31 (6.8) | 22 (5.3) | 0.455 | 29 (6.4) | 24 (5.7) | 0.790 |
| BMI, kg/m2 | 25.6 (12.8–59.2) | 24.6 (14.3–63.5) | 0.030* | 26.4 (14.3–59.2) | 24.2 (12.8–63.5) | < 0.000001* |
| BMI > 30 kg/m2 (obesity), n, % of all | 91 (22.8) | 51 (15.5) | 0.016* | 102 (26.1) | 40 (11.8) | < 0.00001* |
| Laboratory data | ||||||
| HDL cholesterol, mg/dL | 40 (16–103) | 39.1 (6–103) | 0.719 | 33 (6–82) | 47 (19–103) | < 0.000001* |
| Triglycerides, mg/dL | 172.5 (40.6–856) | 121 (29.8–585) | < 0.00001* | 201 (46–856) | 109 (29.8–260) | < 0.000001* |
| LDL cholesterol, mg/dL | 120.1 (41.8–512) | 73.4 (13.3–99.5) | < 0.00001* | 102.4 (17–512) | 93 (13.3–255) | 0.0004* |
| Non-HDL cholesterol, mg/dL | 158.7 (53.6–593) | 99 (27–157) | < 0.00001* | 148 (44–593) | 116.7 (27–282) | < 0.000001* |
| Adropin, ng/mLb | 2.02 (0.22–8.01) | 2.15 (0.76–8.46) | 0.491 | 1.85 (0.22–6.98) | 2.46 (0.87–8.46) | 0.002* |
| ALT, IU/L | 14 (0.6–195) | 13 (2–131) | 0.243 | 13 (2–195) | 14 (0.6–135) | 0.922 |
| PTH, pg/mL | 407.7 (7.3–3757) | 355.3 (13.7–2991.5) | 0.082 | 413 (19.5–3118.3) | 361.4 (7.3–3757) | 0.063 |
aThe Mann-Whitney U test was used to compare continuous variables. Chi-squared test with Yates correction was applied to compare dichotomous variables
bDetermined in 126 patients: 67 with dyslipidaemia and 59 without dyslipidaemia by K/DOQI criteria; 73 with atherogenic dyslipidaemia and 53 without atherogenic dyslipidaemia
Abbreviations: ALT alanine aminotransferase, BMI body mass index, ESRD end-stage renal disease, LF-HD low flux haemodialysis, HD haemodialysis, PTH parathyroid hormone, RRT renal replacement therapy, TC total cholesterol, TG triglycerides
P-values below 0.05 are indicated by an asterisk